8-K: SS Innovations Achieves Landmark First Robotic Cardiac Surgery in the Americas with SSi Mantra 3 System

SS Innovations International, Inc. announced the successful completion of the first robotic cardiac surgery in the Americas and Western Hemisphere using its SSi Mantra 3 surgical robotic system.

Summary

• On June 16, 2025, SS Innovations International, Inc. (Nasdaq: SSII) announced a significant medical milestone: the successful completion of the first robotic cardiac surgery in the Americas and Western Hemisphere utilizing its SSi Mantra 3 surgical robotic system.
• The groundbreaking procedure, a robotic Atrial Septal Defect closure (repairing a hole between the upper two chambers of the heart), was performed on June 8, 2025, by Dr. Juan Zuniga, a cardiothoracic surgeon at Interhospital in Guayaquil, Ecuador.
• Interhospital is noted as the first hospital in South America to install the SSi Mantra system, and has previously used it for various complex surgical procedures.
• The SSi Mantra 3 system is described as a user-friendly, modular, multi-arm system featuring 3 to 5 robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, and a touch panel for patient information.
• The system supports over 40 different types of robotic endo-surgical instruments and has been clinically validated in India across more than 100 different surgical procedures.

Sentiment

Score: 9

Explanation: The document reports a significant and successful medical milestone (first robotic cardiac surgery in a major region) for the company's flagship product, indicating strong product performance and market expansion potential.

Positives

• Successful completion of the first robotic cardiac surgery in the Americas and Western Hemisphere marks a significant technological and regional milestone for SS Innovations.
• The SSi Mantra 3 system demonstrated ease of handling and manipulation, as noted by Dr. Juan Zuniga, leading to effective results and complete closure verification via transesophageal echocardiogram.
• Patient recovery was described as 'very well' and 'much faster' due to the minimally invasive nature of the robotic procedure, with less bleeding and more precise tissue manipulation and suturing.
• The successful cardiac surgery expands the clinical validation and application of the SSi Mantra 3 system into complex specialties like cardiovascular surgery.
• Interhospital in Ecuador, the first in South America to adopt the SSi Mantra, has successfully utilized the system for a variety of complex surgical procedures, indicating broader utility and acceptance.

Risks

• Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied.

Future Outlook

SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions, aiming to make robotic surgery affordable and accessible to a larger segment of the global population.

Management Comments

• Dr. Juan Zuniga, cardiothoracic surgeon at Interhospital: "On the heels of SSi Mantras debut in Latin American robotic surgeries, we decided to leverage this advanced system in complex specialties, particularly in cardiovascular surgeries. The experience was good, this equipment was very easy to handle and manipulate, and the results were effective as we did a transesophageal echocardiogram to verify the complete closure of the communication between the two upper chambers of the heart. We were very happy with the results in achieving a successful closure and the patient is recovering very well."
• Dr. Juan Zuniga: "Because it is a minimally invasive procedure, the recovery is much faster, bleeding much less, and since it is done robotically, the manipulation of the tissues is much more precise, and so is the suturing. It gives the surgeon the confidence that every stitch that is made with the platform is placed precisely and without complication."

Industry Context

This announcement positions SS Innovations as a key player in the expanding global robotic surgery market, particularly in making advanced surgical technologies more affordable and accessible. The successful cardiac surgery in the Americas highlights the growing adoption of robotic systems in complex medical procedures and the potential for market penetration in regions seeking cost-effective, high-precision solutions.

Comparison to Industry Standards

• The successful completion of the 'first robotic cardiac surgery in the Americas and Western Hemisphere' using the SSi Mantra 3 system establishes a new regional benchmark for robotic surgical capabilities.
• While no specific comparable companies or projects are named, this achievement demonstrates SS Innovations' ability to compete in the highly specialized and competitive field of robotic cardiac surgery, traditionally dominated by established players like Intuitive Surgical (with its da Vinci system).

Stakeholder Impact

• Shareholders: Positive news regarding product validation and market expansion could lead to increased investor confidence and potential share price appreciation.
• Patients: Access to advanced, minimally invasive robotic cardiac surgery, potentially leading to faster recovery and better outcomes.
• Surgeons: Provides a user-friendly and precise tool for complex procedures, enhancing surgical capabilities and confidence.
• Hospitals: Offers an advanced surgical robotic system that has demonstrated efficacy in complex procedures, potentially attracting more patients and enhancing institutional reputation.
• Employees: Positive validation of the company's technology and strategic direction, potentially boosting morale and future opportunities.

Next Steps

• SS Innovations plans to expand the global presence of its surgical robotic solutions.

Key Dates

Keywords

Surgical Robotics, Cardiac Surgery, SSi Mantra 3, Minimally Invasive Surgery, Medical Devices, Healthcare Technology, Ecuador, Atrial Septal Defect, Interhospital, SS Innovations International